Condition: Mantle Cell Lymphoma · Sponsor: H. Lee Moffitt Cancer Center and Research Institute
This is a phase 2, open-label, randomized, multicenter clinical trial in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) who meet the criteria for standard-of-care FDA label for CD19 CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel).
This description comes directly from the study's public registry record.
Ruthie Chae · 813-745-3425 · ICETtrials@moffitt.org
Always discuss trial participation with your own doctor first.
| Stanford Cancer Center | Stanford, California, United States | Not Yet Recruiting |
| Univ of Miami - Sylvester Comprehensive Cancer Center | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06553872